发现甲基化循环DNA生物标志物用于全面无创监测转移性结直肠癌治疗反应
研究通过全基因组甲基化微阵列在149种结直肠癌细胞系中鉴定出五个癌症特异性甲基化位点(EYA4、GRIA4、ITGA4、MAP3K14-AS1、MSC),并用数字PCR在82份肿瘤组织DNA和182例转移性结直肠癌患者cfDNA中验证;至少一个标志物甲基化在全部肿瘤组织样本和156份(85.7%)患者cfDNA中检出,甲基化动态与客观肿瘤缓解及无进展生存相关。
要点
- 五个基因甲基化面板可在转移性结直肠癌cfDNA中检出,至少一个标志物阳性者占85.7%(156/182)。
- 血浆各标志物阳性率:EYA4 71.4%、GRIA4 68.5%、ITGA4 69.7%、MAP3K14-AS1 69.1%、MSC 65.1%。
- 甲基化标志物动态不受治疗类型影响,与客观肿瘤缓解和无进展生存相关。
核心结论
- 五基因甲基化面板可规避患者特异性突变缺失的问题,用于液体活检监测不同治疗方案下的肿瘤负荷动态。
- 该方法可能被提出用于临床试验中评估药效学,或当常规影像学检查受限时使用。
研究设计与样本
- 研究对149种结直肠癌细胞系进行全基因组甲基化微阵列分析,鉴定出五个癌症特异性甲基化位点。
- 采用数字PCR检测82份肿瘤组织DNA和182例转移性结直肠癌患者cfDNA中这些基因的甲基化。
- 对接受化疗或靶向治疗的患者亚组进行血浆纵向评估。
主要发现
- 至少一个标志物甲基化在全部肿瘤组织样本中检出,在156份转移性结直肠癌患者cfDNA样本中检出(85.7%)。
- 血浆标志物阳性率分别为EYA4 71.4%、GRIA4 68.5%、ITGA4 69.7%、MAP3K14-AS1 69.1%、MSC 65.1%。
- 甲基化标志物动态不受治疗类型影响,与客观肿瘤缓解和无进展生存相关。
临床怎么用
- 原文结论指出,五基因甲基化面板可用于液体活检监测不同治疗方案下的肿瘤负荷动态。
- 原文结论指出,该方法可能被提出用于临床试验中评估药效学,或当常规影像学检查受限时使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mutations in cell-free circulating DNA (cfDNA) have been studied for tracking disease relapse in colorectal cancer (CRC). This approach requires personalised assay design due to the lack of universally mutated genes. In contrast, early methylation alterations are restricted to defined genomic loci allowing comprehensive assay design for population studies. Our objective was to identify cancer-specific methylated biomarkers which could be measured longitudinally in cfDNA (liquid biopsy) to monitor therapeutic outcome in patients with metastatic CRC (mCRC). DESIGN: Genome-wide methylation microarrays of CRC cell lines (n=149) identified five cancer-specific methylated loci (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC). Digital PCR assays were employed to measure methylation of these genes in tumour tissue DNA (n=82) and cfDNA from patients with mCRC (n=182). Plasma longitudinal assessment was performed in a patient subset treated with chemotherapy or targeted therapy. RESULTS: Methylation in at least one marker was detected in all tumour tissue samples and in 156 mCRC patient cfDNA samples (85.7%). Plasma marker prevalence was 71.4% for EYA4, 68.5% for GRIA4, 69.7% for ITGA4, 69.1% for MAP3K14-AS1% and 65.1% for MSC. Dynamics of methylation markers was not affected by treatment type and correlated with objective tumour response and progression-free survival. CONCLUSION: This five-gene methylation panel can be used to circumvent the absence of patient-specific mutations for monitoring tumour burden dynamics in liquid biopsy under different therapeutic regimens. This method might be proposed for assessing pharmacodynamics in clinical trials or when conventional imaging has limitations.
引用
- Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2017. PMID: 28982739. doi:10.1136/gutjnl-2016-313372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。